KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma.

Yuwen Jin, Benjamin Guiastrennec, Miriam Stuke, Yuhui Yao, Yajuan Zhang, Peter Barker, Maria Jison, Robert C Penland, Junjie Ding, Pradeep B Lukka

Clin Pharmacokinet 64(8) 1231-1243

PMID40551003
PMCIDPMC12263781
DOI10.1007/s40262-025-01538-9
发表日期2025-06-23
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

INTRODUCTION: Benralizumab is approved as add-on subcutaneous therapy in patients aged ≥ 12 years with severe eosinophilic asthma in > 80 countries, including mainland China. OBJECTIVE: The study objective was to update benralizumab population pharmacokinetic (popPK) and exposure-response (ER) models in Chinese, Asian (including Chinese), and non-Asian participants. METHODS: Benralizumab popPK/ER models for asthma exacerbation rate and pre-bronchodilator forced expiratory volume in 1 second (FEV1) were updated for three benralizumab trials involving Chinese, Asian (including Chinese), and non-Asian participants. The ER analysis examined correlations between pharmacokinetic quartiles and annual asthma exacerbation rate (AAER) ratios with simulations comparing predicted clinical outcomes. RESULTS: Updated data included 17,465 benralizumab concentrations (n = 2855). The updated model predicted a slight, and not clinically relevant, increase (< 14%) in benralizumab exposure for Chinese versus non-Asian adults. Median exposure increased in Chinese adolescents versus adults owing to body weight differences, but no dose adjustment was needed. Chinese children weighing < 35 kg receiving a 10 mg dose had similar exposure to those weighing ≥ 35 kg receiving a 30 mg dose. In Chinese versus non-Chinese participants, there was no trend concerning AAER ratios across different trough concentration quartiles; the maximal treatment effect significantly increased (+127%; p < 0.001), and there was no statistically significant effect on pre-bronchodilator FEV1. Steady-state simulations showed lower predicted AAER ratios in Chinese (0.38; 95% confidence interval [CI] 0.32-0.45) than in non-Chinese adults (0.64; 95% CI 0.60-0.71), and no relevant differences between Chinese adults (0.46; 95% CI 0.38-0.54) and adolescents (0.46; 95% CI 0.37-0.55). CONCLUSION: The benralizumab popPK/ER models showed good predictive performance across Chinese demographics. TRIAL REGISTRATION NUMBER: NCT03186209. TRIAL REGISTRATION DATE: 6 July 2017.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Schema of modeling strategy for the updated population pharmacokinetic analysis. PK pharmacokinetic, popPK population pharmacokinetic
非 KM Figure
Fig. 2Fig. 2 Comparison of the distribution of simulated benralizumab exposure metrics between Chinese adults and adolescents. Numbers show the simulated population medians (dots) and the 5th and 95th percentiles (error bars) from 200 replicates of 500 participants. C avg average concentration, C trough trough concentration, C max maximum concentration
非 KM Figure
Fig. 3Fig. 3 Visual predictive checks of the adults-only model extrapolated to the adolescents-only data. CI confidence interval
非 KM Figure
Fig. 4Fig. 4 Distribution of simulated exposure metrics in adults at steady state (under benralizumab 30 mg every 8 weeks) by summary statistics and Chinese/non-Asian race. Numbers on the boxplots show the 25th percentile, the median, and the 75th percentiles. C avg average concentration, C trough trough concentration, C max maximum concentration.
非 KM Figure
Fig. 5Fig. 5 Exacerbation rate ratios by quartiles of benralizumab trough concentration for the benralizumab every-8-week dosing regimen, stratified by Chinese and non-Chinese race. Dots and error bars represent estimated exacerbation rate ratios and 95% confidence interval. Pharmacokinetic quartile definition for every-8-week administration: Q1 = 0–140 ng/mL, Q2 = 140–256 ng/mL, Q3 = 256–442 ng/mL, Q4 = 442–2080 ng/mL. Q1–4 benralizumab trough concentration quartile defined per regimen.
非 KM Figure
Fig. 6Fig. 6 Predicted annual asthma exacerbation rate (AAER) ratio at steady state for the benralizumab every-8-week dosing regimen, stratified by Chinese and non-Chinese race, and for Chinese adult, adolescent, and pediatric participants. The predicted AAER is shown by blue squares and its 95% confidence interval (error bars). Children with body weight ≥ 35 kg received subcutaneous benralizumab 30 mg every 8 weeks, and children weighing < 35 kg received subcutaneous benralizumab 10 mg every 8 weeks
非 KM Figure